RxDoctor Payments Data

Angela Houfek, PA

Physician Assistant · Green Bay, WINPI 1497312300

Payments from drug & device makers

$493in general payments, 2019–2025

Across 20 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BETA Bionics, Inc.$149
  • Novo Nordisk$119
  • Lilly USA, LLC$38
  • Averitas Pharma Inc.$24
  • Medtronic$24
  • Xeris Pharmaceuticals, Inc.$20
  • plus $119 from 7 others

What the payments were for

  • Food & beverage$493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$493 in reported general payments places this provider in the 80th percentile of 2,804 physician assistant providers in Wisconsin.

See all physician assistant providers in Wisconsin

Medicare billing

Part B allowed, 2024
$25,317
Medicare patients
73
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide187$271,640
OzempicSemaglutide103$162,698
Tresiba Flextouch U-200Insulin Degludec59$158,857
JardianceEmpagliflozin128$149,307
TrulicityDulaglutide64$94,018
Humalog Kwikpen U-200Insulin Lispro20$71,513
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog52$71,236
Tresiba Flextouch U-100Insulin Degludec78$69,460
Fiasp FlextouchInsulin Aspart (Niacinamide)35$64,552
Humulin R U-500 KwikpenInsulin Regular, Human18$45,311
Humalog Kwikpen U-100Insulin Lispro80$37,111
Lantus SolostarInsulin Glargine,hum.Rec.Anlog169$33,285
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$24,748
Lyumjev Kwikpen U-100Insulin Lispro-Aabc18$23,692
RybelsusSemaglutide21$22,722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$38$375,284281 claims
Novo NordiskOzempic, Rybelsus$119$185,420124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,804 physician assistant providers in Wisconsin.

Other physician assistant in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →